A total of 0.8 μM of heteronemin in HT-29 cells (KRAS WT CRC) or 0.4 μM of heteronemin in HCT-116 cells (KRAS MT CRC) and 10−7 M of tetrac were further used to identify whether tetrac enhanced the antitumor effect of heteronemin in human CRC cells with different KRAS statuses. Here, KRAS is linked to colorectal carcinoma.